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Objectives. We sought to compare the predictive value of
echocardiographically determined left ventricular hypertrophy on
death from all causes and cardiac mortality using various meth-
ods of indexation for left ventricular mass.
Background. Considerable controversy exists regarding the
optimal method for indexing left ventricular mass to body size in
the clinical setting.
Methods. The study included 988 consecutive patients who had
both coronary angiograms and echocardiographic examinations
in an inner-city public hospital in Chicago, Illinois. Patients were
followed up for a mean of 7 years (range 2 to 11).
Results. Various left ventricular mass indexes (e.g., mass
indexed for height, height2, height2.13, height2.7, body surface area
and body surface area1.5 were highly correlated (r 5 0.90 to 0.99).
Used as a continuous measure, an increase in any left ventricular
mass index was associated with similar risk of death from all
causes and cardiac diseases. Although left ventricular hypertro-
phy assessed by mass indexed for body surface area using the
published conventional partition values provided somewhat better
prediction, the adjusted relative risk was in general not signifi-
cantly different from hypertrophy based on other indexes. Patients
with left ventricular hypertrophy defined concordantly by indexes
based on both body surface area and height (or height2.7) had, by
definition, the highest average mass indexes among all groups and
experienced as much as a threefold greater risk of death than
those without hypertrophy. A small proportion of patients (12%)
who were classified into the hypertrophy group by height-based
indexes alone, but not by body surface area, had a moderate
increase in mass and showed no increase in risk, even though
being overweight was extremely prevalent in this group.
Conclusions. Because of the high correlation among various
body size indexes, left ventricular hypertrophy, defined by differ-
ent indexes for left ventricular mass, similarly confers increased
risk of mortality in patients with or without coronary artery
disease.
(J Am Coll Cardiol 1997;29:641–7)
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Echocardiographically determined left ventricular hypertro-
phy indexed for either body surface area or height has been
shown to be an independent predictor of cardiovascular
morbidity and mortality (1–5). Recently, height2.0 (6),
height2.13 (7,8), height2.7 (7–9), height3 (10) and body
surface area1.5 (9) have also been proposed as the appro-
priate measure of body size to normalize left ventricular
mass. This study compares the impact of various methods of
indexation for left ventricular mass on mortality in a
hospital-based patient series.
Methods
Study patients. Between January 1983 and June 1991,
2,971 consecutive patients underwent cardiac catheterization
for diagnostic evaluation of presumed coronary artery disease in
Cook County Hospital, a public general hospital in Chicago,
Illinois, serving a primarily minority population. A satisfactory
echocardiogram had been performed on 1,317 patients. This
analysis excluded 295 patients with impaired systolic function
(ejection fraction ,45%) to eliminate the confounding effect of
impaired contractility of the left ventricle on the relation between
left ventricular mass and prognosis. Patients with asymmetric
septal hypertrophy (n 5 10) and with missing data on body
surface area (n 5 24) were also excluded. The final analytic
cohort for this study thus consisted of a total of 988 patients.
Body surface area was calculated using the formula:
0.0001 3 71.84 3 (weight [kg])0.425 3 (height [cm])0.725.
Overweightness was defined according to the National Insti-
tutes of Health Consensus Panel (11) as body mass index
(weight in kilogram per square meter of height) .27.8 in men
and 27.3 in women.
Measurements. Coronary cineangiograms were obtained
in multiple projections, including angulated views in the sagit-
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tal plane. Significant coronary artery disease was defined as
$50% reduction in the diameter of any major coronary artery.
Two-dimensionally guided M-mode echocardiograms were ob-
tained according to the recommendations of the American
Society of Echocardiography (ASE) using a leading edge to
leading edge convention (12). Left ventricular posterior wall
thickness, ventricular septal thickness and left ventricular
internal dimension were measured at end-diastole, as defined
by the onset of the QRS complex. Left ventricular mass was
calculated using the modification by Devereux et al. (13) of the
ASE cube formula:
0.8~1.04 @Left ventricular internal diameter
1 Left ventricular septal thickness1 Posterior wall thickness]3
2 @Left ventricular internal diameter#3)1 0.6.
This formula has been anatomically validated, and values
obtained using this formula were similar to those obtained with
the Penn cube method (13). There are currently more than a
dozen criteria with various left ventricular indexation and
partition values used to define the presence of left ventricular
hypertrophy (14). In this report we selected the criteria
originally derived from the same population samples and
widely used in cohort studies (1,2,4,5,7–9,15,16). In the Fram-
ingham Heart Study, the mean values 6 2 SD were 131 and
100 g/m2 for men and women, respectively, for left ventricular
mass indexed by body surface area (15). The corresponding
values were 143 and 102 g/m, respectively, for mass/height, and
259 and 166 g, respectively, for unindexed mass. The partition
values reported by de Simone et al. (8) for 97.5 percentile of
mass/body surface area, mass/height and mass/height2.7 were
117 g/m2, 126 g/m and 50 g/m2.7 for men and 104 g/m2, 105 g/m
and 47 g/m2.7 for women, respectively. The nongender-specific
upper limit of 51 g/m2.7 has also been suggested for mass
indexed by height2.7 (8). In addition, the partition value of
125 g/m2 for both men and women has been used for mass
indexed by body surface area in several studies (1,4).
Follow-up. An attempt was made to contact all patients
either during an outpatient visit, by telephone or by review of
medical records of clinic attendance. In addition, the data base
provided by the National Death Index, which contains a
standard set of identifying data for each decedent of the
nation, was searched annually until December 31, 1993, for all
members of the original cohort (17). Death certificates of the
decedents were obtained from the Department of Public
Health in the states where the patients died. Patients who were
not contacted and thus not confirmed to be alive and who were
not matched to a death certificate were considered alive as of
the last date included in the National Death Index File.
Data analysis. The relations among continuous variables
(e.g., various left ventricular mass indexes) were examined
using Pearson correlation analyses. A Cox proportional haz-
ards model was used to examine the risk of all causes of death
and cardiac death for different mass indexes in the following
manner: First, each left ventricular mass index was entered in
the Cox regression models as a continuous measurement. To
assure the comparable scales for all mass indexes, the mea-
surements were log-transformed and standardized into a Z
score. The relative risks and their 95% confidence intervals
were calculated for each Z score (a standardized unit) increase
in left ventricular mass index. Then, risks were estimated for
left ventricular hypertrophy defined by each mass indexation
and published partition value. Finally, left ventricular hyper-
trophy defined by two different mass indexations (e.g., body
surface area and height or body surface area and height2.7)
were considered simultaneously. The definitions of left ven-
tricular hypertrophy for various indexes were derived from the
same population sample (8). We cross-classified patients by
body surface area and height (or height2.7) and examined the
pattern of relative risk among those in the concordant and
discordant cells. Three indicator variables representing four
different combinations of the two dichotomized measures were
tested in the Cox regression model.
The analyses were first performed separately for men and
women. As previously reported (18), the excess risk of mortal-
ity associated with increasing left ventricular mass was greater
in women than in men among patients without coronary artery
disease. However, risk comparisons among different mass
indexes within the same gender followed similar patterns for
men and women. Hence, combined data were presented in the
report with adjustment for gender.
Left ventricular mass indexed for various measures of body
size are highly correlated and are not independent from each
other. Hence, devising a formal test to compare the two
relative risks associated with different indexes is complex. We
used a computer-intensive method—bootstrap resampling
(19)—to test whether the observed differences between two
Cox coefficients were unusually large. We randomly drew
samples (with replacement) from the study cohort and com-
puted the difference between two Cox coefficients. This pro-
cedure was repeated 1,000 times and the variance of the
difference in Cox coefficients was estimated. The null hypoth-
esis was rejected if the 95% confidence interval of the differ-
ence did not include 0.
Results
Baseline data. The demographic and clinical characteris-
tics by angiographically-defined coronary anatomy are shown
in Table 1. Of 988 patients, 531 (54%) had one or more
obstructed coronary vessels. Most of the patients were black
(82%) and had a history of hypertension (83%). More than
half of the patients were overweight. Left ventricular hyper-
Abbreviations and Acronyms
ASE 5 American Society of Echocardiography
CI 5 confidence interval
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trophy was present in 41% to 50% of the patients without
coronary artery disease and in 49% to 57% of those with
coronary artery disease, depending on the criteria used to
define hypertrophy. The various mass indexes were highly
correlated with the Pearson correlation coefficients (r) ranging
from 0.92 to 0.99 among height-based indexes, and from 0.90
to 0.97 between height-based and body surface area-based
indexes. The coefficients were 0.81 to 0.98 between unindexed
and indexed mass. Among patients with coronary artery dis-
ease there was a weak but statistically significant correlation
(r 5 0.09 to 0.14) between mass indexes and age, which was
itself strongly associated with mortality. Thus, further analyses
were done with adjustment for age.
Left ventricular mass indexes as continuous measures.
During a mean follow-up of 7 years (range 2 to 11), 202
patients died (142 patients with and 60 patients without
coronary artery disease at baseline), among whom 127 died
from cardiac diseases (95 patients with and 32 patients without
coronary artery disease). The multivariate-adjusted relative
risks and 95% confidence intervals for the two fatal end points
associated with each Z-score increase in left ventricular mass
and mass indexes are presented in Table 2. All the standard-
ized relative risks were similar regardless of the indexes used.
None of the risk estimates was significantly different by the
computer-intensive method.
Predictive values of left ventricular hypertrophy based on
different indexes. Table 3 shows the relative risks by left
ventricular hypertrophy defined by various criteria. With only a
few exceptions, all the relative risks were significantly different
from 1.0 (p , 0.05). In Table 3, criteria to define left
ventricular hypertrophy by unindexed mass (item 1), mass/
body surface area (item 2) and mass/height (item 5) were
derived from the Framingham Study (16). Mass/body surface
area (item 3); mass/height (item 6); mass/height2.7, nongender-
specific criteria (item 7); and mass/height2.7, gender-specific
criteria (item 8) were from the same adult samples reported by
de Simone et al. (8). Pairwise comparisons across criteria
within the same study samples showed that most of the
Table 1. Baseline Characteristics of Patients With or Without
Coronary Artery Disease
Without CAD
(n 5 457)
With CAD
(n 5 531)
Age (yr) 53.56 9.6 56.9 6 9.0
Female (%) 65.2 47.1
Black (%) 86.7 78.2
Hypertension (%) 81.8 83.4
Diabetes (%) 18.6 31.5
Overweight (%) 60.8 53.5
Body mass index (kg/m2) 29.7 6 6.1 28.4 6 5.4
Ejection fraction (%) 706 10 65 6 11
Echocardiographic data
Posterior wall thickness (cm) 1.16 0.2 1.2 6 0.2
Interventricular septal thickness (cm) 1.26 0.2 1.2 6 0.2
LV end-systolic dimension (cm) 3.06 0.8 3.3 6 0.9
LV end-diastolic dimension (cm) 4.76 0.7 4.9 6 0.8
LV mass (g) 2086 75 230 6 83
LV mass index/BSA (g/m2)* 109 6 39 122 6 42
LV mass index/height (g/m)* 1256 44 137 6 48
LV mass index/height2.7 (g/m2.7)* 53 6 20 57 6 21
Prevalence of LV hypertrophy [no. (%)]
Corrected for BSA 177 (39%) 255 (48%)
Corrected for height 223 (49%) 295 (56%)
Corrected for height2.7 190 (42%) 278 (52%)
*Definitions of left ventricular (LV) hypertrophy are left ventricular mass/
body surface area (BSA) $131 g/m2 in men and $100 g/m2 in women; left
ventricular mass/height $143 g/m in men and $102 g/m in women; and left
ventricular mass/height2.7 $51 g/m2.7 for both men and women. Data presented
are mean value 6 SD, unless otherwise indicated. CAD 5 coronary artery
disease.
Table 2. Adjusted* Relative Risk (95% confidence interval) Associated With Each Standardized Unit
Increase in Various Left Ventricular Mass Indexes
Indexation for LV Mass
Without CAD With CAD
All-Cause
Death
Cardiac
Death
All-Cause
Death
Cardiac
Death
Unindexed LV mass 1.80 1.92 1.39 1.38
(1.43–2.26) (1.41–2.62) (1.18–1.63) (1.14–1.69)
LV mass indexed for height 1.71 1.79 1.38 1.39
(1.35–2.15) (1.31–2.46) (1.17–1.63) (1.14–1.70)
LV mass indexed for height2 1.60 1.66 1.36 1.39
(1.27–2.03) (1.20–2.28) (1.15–1.61) (1.13–1.70)
LV mass indexed for height2.13 1.59 1.64 1.36 1.39
(1.26–2.01) (1.19–2.26) (1.15–1.61) (1.13–1.70)
LV mass indexed for height2.7 1.53 1.56 1.34 1.38
(1.21–1.93) (1.13–2.15) (1.13–1.59) (1.12–1.69)
LV mass indexed for BSA 1.74 1.82 1.43 1.47
(1.38–2.18) (1.34–2.46) (1.22–1.69) (1.21–1.79)
LV mass indexed for BSA1.5 1.69 1.75 1.44 1.49
(1.35–2.12) (1.29–2.37) (1.22–1.70) (1.23–1.82)
*Adjustment for age and gender; all relative risks are significantly different from 1.0 (p , 0.01). Abbreviations as in
Table 1.
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observed differences in relative risk were not statistically
significant. A few exceptions were identified. Relative risks in
item 3 (hypertrophy defined by mass/body surface area) were
significantly greater than those in item 8 (mass/height2.7,
gender-specific criteria). Significant differences were also
found when comparing body surface area indexation with that
indexed by height for cardiac death among patients without
coronary artery disease (relative risk 3.7 in item 3 vs. 2.4 in
item 6 and 3.7 in item 2 vs. 2.6 in item 5).
Left ventricular hypertrophy cross-classified by two in-
dexes. When patients were cross-classified as having left ven-
tricular hypertrophy by two indexes, two concordant and two
discordant groups were identified. The number of patients in
each of the four groups varied according to the indexes and the
partition values for hypertrophy used. Table 4 shows selected
variables for the four groups using mass/body surface area and
mass/height with the definitions for hypertrophy derived from
a recent study (8). Patients classified as having hypertrophy
simultaneously by two indexes had the highest average left
ventricular mass and mass indexes (Table 4 and Fig. 1). They
had a significantly increased risk of mortality compared with
those without hypertrophy by both indexes (adjusted relative
risk was 3.5 (95% confidence interval [CI] 2.0 to 6.3) and 3.1
(95% CI 1.5 to 6.6) for all causes of death and cardiac death,
respectively, among patients without coronary artery disease.
For patients with coronary artery disease, the relative risk was
1.8 (95% CI 1.2 to 2.6) and 2.0 (95% CI 1.2 to 3.2), respec-
tively. In a small proportion of patients, hypertrophy was
detected by mass indexed for height but not for body surface
area. By definition, these patients had only moderate increases
in ventricular mass and had the highest body mass index and
prevalence of overweightness among all groups (p , 0.01)
(Table 4). No increased risk of either fatal end point was
observed (relative risk 0.1 to 0.8, p . 0.05). The number of
patients classified with hypertrophy only by mass indexed for
body surface area was very small and no inference could be
derived. The results followed a similar pattern when mass
indexed for body surface area and for height2.7 were consid-
ered together (data not shown). Again, left ventricular hyper-
trophy identified by both indexes was associated with a signif-
icantly increased risk of death. Little evidence of an increase in
risk was found in patients with hypertrophy detected by mass
indexed for height2.7 but not for body surface area.
Discussion
Indexation of left ventricular mass to body size. Since the
19th century, many aspects of human metabolism and organ
growth have been “normalized” by body surface area (20). This
indexation has subsequently been applied to cardiovascular
measurements, including ventricular mass (21–24). Height was
chosen as a measure of body size because it is obesity
independent (25), and the linear growth determined by height
was the major factor influencing left ventricular mass in
children and young adults (26). Recently, many other indexes
have been proposed as the more appropriate measure of body
Table 3. Adjusted* Relative Risk (95% confidence interval) in Patients With Left Ventricular
Hypertrophy Defined by Various Left Ventricular Mass Indexations and Partition Values
LV Hypertrophy
Without CAD With CAD
All-Cause
Death
Cardiac
Death
All-Cause
Death
Cardiac
Death
1. Defined by unindexed LV mass
$259 g in men, 166 g in women
2.7 2.8 2.0 1.9
(1.6–4.8) (1.3–6.0) (1.4–2.9) (1.2–3.1)
Defined by LV mass/BSA
2. $131 g/m2 in men, 3.5 3.7 2.1 2.1
$100 g/m2 in women (2.0–6.1) (1.8–7.9) (1.5–3.0) (1.3–3.2)
3. $117 g/m2 in men, 3.8 3.7 1.9 2.1
$104 g/m2 in women (2.2–6.6) (1.8–7.9) (1.3–2.6) (1.4–3.3)
4. $125 g/m2 in both men and 3.9 4.5 1.9 1.7
women (2.3–6.5) (2.2–9.2) (1.4–2.7) (1.2–2.6)
Defined by LV mass/height
5. $143 g/m in men, 2.9 2.6 1.7 1.7
$102 g/m in women (1.7–5.1) (1.2–5.6) (1.2–2.5) (1.1–2.7)
6. $126 g/m in men, 2.8 2.4 1.6 1.7
$105 g/m in women (1.6–5.0) (1.1–5.1) (1.1–2.3) (1.1–2.7)
Defined by LV mass/height2.7
7. $51 g/m2.7 in both 3.0 3.3 1.5 1.5†
men and women (1.7–5.1) (1.5–6.9) (1.1–2.1) (1.0–2.3)
8. $50 g/m2.7 in men, 2.3 2.6 1.4† 1.4‡
$47 g/m2.7 in women (1.3–4.0) (1.2–5.5) (1.0–2.0) (0.9–2.2)
*Adjustment for age and gender; all relative risks are significantly different from 1.0 except for †p , 0.10 and p .
0.05 and ‡p . 0.05. Abbreviations as in Table 1.
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size to use in normalizing left ventricular mass (6–10). Resid-
ual relations of mass/body surface area to body surface area
and of mass/height to height were markedly reduced by
normalization of ventricular mass for height2.7. However, a
weak inverse association between mass/height2.7 and height
has also been demonstrated (6,9), which may indicate possible
overadjustment. In fact, intragroup variability of ventricular
mass was essentially the same regardless of the indexes used,
except for height, where it was somewhat greater (9). Different
methods of indexation had a minimal effect on the observed
association between left ventricular mass and systolic blood
pressure (6).
Predictive values of different methods of indexation. Left
ventricular hypertrophy defined by mass indexed for body
surface area or height has long been known to be an indepen-
dent predictor of cardiovascular morbidity and mortality (1–5).
Recently, de Simone et al. (8) reported that height-based
indexes of left ventricular mass at least maintained or perhaps
enhanced risk prediction; the former but not the latter out-
come was supported by this study. Given the high degree of
correlation between the different indexes of left ventricular
mass, it is not surprising that we found no differences in the
mortality risks for the different indexes when considered as
continuous measures. Only when partition values were used to
define hypertrophy did any indication of prognostic differences
arise. This outcome is a result of the fact that the normal limits
for these different indexes were mostly derived from the
studies with small sample sizes in each gender group (8,22).
Impact of overweight. Many studies have suggested that
normalization of left ventricular mass for body surface area or
height introduces artifacts into the relation between heart size
and body size and underestimates the impact of overweight
(6,7,9,15,25,27). The prevalence rates of left ventricular hyper-
trophy, correcting mass for body surface area, were less than
those when correction was made for height or height2.7
(7,9,15,27). The allometric signal for height was proposed as
the optimal index for body size, which would prevent errone-
ously categorizing obesity-induced left ventricular hypertrophy
as normal. However, use of body surface area correction
attenuated but did not eliminate the observed relations be-
tween obesity and echocardiographic left ventricular variables
(27–29). Except for “obesity cardiomyopathy,” which occurs in
very obese patients (30), the clinical course and prognostic
implication of minor or moderate changes in left ventricular
size, assumed to be caused by obesity, are not yet clear (6,28).
Study limitations. The data for this study were obtained
from a hospital registry and may be subject to a certain degree
of selection bias. All the patients had undergone angiographic
and echocardiographic examination. The patients were pre-
dominantly blacks and had a high prevalence of hypertension,
overweightness and left ventricular hypertrophy. The general-
izability of the results needs to be examined in separate
populations. Morbidity data were not available for patients in
this cohort. This study therefore cannot exclude the possibility
that obesity-related left ventricular hypertrophy may increase
morbid cardiovascular events before an overt survival disad-
vantage becomes apparent.
Conclusions. These data from a clinical setting indicate
that left ventricular hypertrophy, defined by various body size
indexes for left ventricular mass, similarly confers increased
risk of mortality in patients with or without coronary artery
disease. Patients with hypertrophy defined by both a body
surface area index and a height-based index had the greatest
mass indexes and hence the greatest risk. No increased mor-
tality was found for hypertrophy detected by height-based
indexes in the absence of hypertrophy based on criteria that
indexed for body surface area. These patients were usually
overweight and had a lower degree of hypertrophy. The
Table 4. Selected Characteristics According to Presence or Absence of Left Ventricular Hypertrophy Defined by Left Ventricular Mass
Indexed for Body Surface Area* and Mass Indexed for Height†
LVH Defined by Mass/BSA: No Yes No Yes
LVH Defined by Mass/Height: No No Yes Yes
Patients Without CAD
No. of pts 218 3 57 179
Body mass index (kg/m2) 28.8 6 5.4 22.5 6 1.9 33.1 6 5.4 29.9 6 6.8
Overweight (%) 54 0 91 60
LV mass (g) 1566 27 182 6 22 198 6 26 271 6 76
LV mass/BSA (g/m2) 81 6 14 111 6 8 100 6 8 143 6 39
LV mass/height (g/m) 926 15 112 6 12 119 6 11 163 6 43
Patients With CAD
No. of pts 199 10 58 264
Body mass index (kg/m2) 26.6 6 4.6 20.4 6 2.6 32.5 6 4.7 29.1 6 5.4
Overweight (%) 37 0 91 59
LV mass (g) 1666 31 186 6 22 202 6 28 283 6 81
LV mass/BSA (g/m2) 89 6 14 113 6 9 100 6 8 150 6 40
LV mass/height (g/m) 986 16 111 6 9 120 6 11 169 6 45
*Defined as left ventricular (LV) mass/body surface area (BSA) $117 g/m2 in men and $104 g/m2 in women. †Defined as left ventricular mass/height $126 g/m
in men and$105 g/m in women. Data presented are mean value6 SD, unless otherwise indicated. CAD5 coronary artery disease; LVH5 left ventricular hypertrophy.
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prognostic implication of ventricular hypertrophy in this small
subset of patients deserves further investigation.
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